In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
EGFR mutations significantly influence NSCLC treatment, with osimertinib showing superior PFS over first-generation TKIs, but resistance remains a challenge. Combination therapies, such as osimertinib ...
In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback